Evotec announced in May of 2022 that the Company has further extended and expanded its collaboration with Bristol Myers Squibb for another 8 years as the initial collaboration proved to be highly ...

AMX0114 is an antisense oligonucleotide made to prevent or slow the degeneration of axons, which is a key driver of ALS ...

RESEARCH TRIANGLE PARK, N.C., April 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2025 financial results on ...

Avidity's delpacibart etedesiran (del-desiran) was granted orphan drug status in Japan as a treatment for myotonic dystrophy ...

A breakthrough study by Irish researchers pinpointed a biomarker for the early identification of the potentially deadly ...

According to the World Health Organization, in 2022 alone, breast cancer killed 670,000 people globally. This type of cancer mostly affects women, although men can also get it. Many famous women have ...

Taken in conjunction with an already-available hormonal therapy – known as fulvestrant – the treatment works by blocking an abnormal or mutated protein molecule, AKT, that drives cancer cells ...

The Institute of Cancer Research, London (ICR) welcomed the move, which follows decades of research by ICR scientists ...

The drug, which is also known as Truqap and made by AstraZeneca, works by blocking the action of an abnormal protein molecule AKT that drives cancer cells to multiply. It therefore helps to slow ...

works by blocking the action of an abnormal protein molecule AKT that causes cancer cells to multiply. It therefore helps to slow or stop the spread of cancer cells. Results from a clinical trial ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Mathematical modeling reveals how population ...